Leading pet wound treatment product developed and produced by Sonoma Pharmaceuticals (Formerly Oculus Innovative Sciences Inc.), a U.S. listed biopharmaceutical company under continuous refinement for over 16 years.
The original and very first hypochlorous acid (HOCl) introduced into the U.S. advanced wound care market.
The Microcyn technology had obtained 17 FDAs, 20 CEs, 73 worldwide patents and undergone 30 clinical trials. It is the world’s best selling hypochlorous (HOCl) wound treatment product healing over 10 million creatures - human and animal. It is used daily in over 20 countries and over 400 hospitals in the U.S.